CompanyKYNBNasdaqSan Francisco, CA

Kyntra Bio

Kyntra Bio develops therapies for oncology and rare disease.

SEC EDGAR ClinicalTrials.gov kyntrabio.com

8-KOct 1Latest SEC filing

Oct 1Latest story

October 2026

Kyntra Bio adds Andrew Singer to board, Maykin Ho departs after eight years

Oct 1PeopleKyntra Bio

August 2026

Kyntra Bio cuts royalty financing cap to $65 million after upfront payment

Aug 31FinancingKyntra Bio

Kyntra Bio reports Q2 2026 results, reaffirms fourth-quarter trial milestones

Aug 13Quarterly updateFG-3246 Kyntra Bio

July 2026

Kyntra Bio registers Phase 3 roxadustat trial for anemia in lower-risk MDS

Jul 23Trial updateKyntra Bio roxadustat